Development of a Web-Based Interactive Tool for Visualizing Breast Cancer Clinical Trial Tolerability Data-Reference-Cited by-同舟云学术

Development of a Web-Based Interactive Tool for Visualizing Breast Cancer Clinical Trial Tolerability Data

Published:2024-07 Issue:8 Volume: Page:
ISSN:2473-4276
Container-title:JCO Clinical Cancer Informatics
language:en
Short-container-title:JCO Clin Cancer Inform

Author:

Luu Michael¹^ORCID,Gresham Gillian¹^ORCID,Henry Lynn²^ORCID,Kim Sungjin¹^ORCID,Rogatko Andre¹^ORCID,Yothers Greg³^ORCID,Hays Ron D.⁴^ORCID,Tighiouart Mourad¹,Ganz Patricia A.⁴⁵^ORCID

Affiliation:

1. Cedars Sinai Medical Center, Department of Computational Biomedicine, Los Angeles, CA

2. University of Michigan Rogel, Cancer Center, Ann Arbor, MI

3. Department of Biostatistics, University of Pittsburgh, Pittsburgh, PA

4. University of California Los Angeles, Department of Medicine, Los Angeles, CA

5. University of California Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA

Abstract

PURPOSE Longitudinal patient tolerability data collected as part of randomized controlled trials are often summarized in a way that loses information and does not capture the treatment experience. To address this, we developed an interactive web application to empower clinicians and researchers to explore and visualize patient tolerability data. METHODS We used adverse event (AE) data (Common Terminology Criteria for Adverse Events) and patient-reported outcomes (PROs) from the NSABP-B35 phase III clinical trial, which compared anastrozole with tamoxifen for breast cancer–free survival, to demonstrate the tools. An interactive web application was developed using R and the Shiny web application framework that generates Sankey diagrams to visualize AEs and PROs using four tools: AE Explorer, PRO Explorer, Cohort Explorer, and Custom Explorer. RESULTS To illustrate how users can use the interactive tool, examples for each of the four applications are presented using data from the NSABP-B35 phase III trial and the NSABP-B30 trial for the Custom Explorer. In the AE and PRO explorers, users can select AEs or PROs to visualize within specified time periods and compare across treatments. In the cohort explorer, users can select a subset of patients with a specific symptom, severity, and treatment received to visualize the trajectory over time within a specified time interval. With the custom explorer, users can upload and visualize structured longitudinal toxicity and tolerability data. CONCLUSION We have created an interactive web application and tool for clinicians and researchers to explore and visualize clinical trial tolerability data. This adaptable tool can be extended for other clinical trial data visualization and incorporated into future patient-clinician interactions regarding treatment decisions.

Publisher

American Society of Clinical Oncology (ASCO)

Link

https://ascopubs.org/doi/pdfdirect/10.1200/CCI.24.00007

Reference23 articles.

1. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

2. Composite grading algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

3. Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index

4. Picture This: Presenting Longitudinal Patient-Reported Outcome Research Study Results to Patients